

Opioid-Related Outcomes Among Individuals With Co-occurring Behavioral Health Conditions

Final Report, September 26, 2022

References

1. Ahmad F, Rossen L, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. Centers for Disease Control and Prevention. Published August 5, 2021. Accessed August 24, 2021. <https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm>
2. Baumgartner JC, Radley DC. The Drug Overdose Toll in 2020 and Near-Term Actions for Addressing It. The Commonwealth Fund. doi:10.26099/gb4y-r129
3. Electronic Code of Federal Regulations (eCFR). Electronic Code of Federal Regulations (eCFR). Accessed June 17, 2021. <https://www.ecfr.gov/>
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). <https://www.psychiatry.org/psychiatrists/practice/dsm>
5. Centers for Disease Control and Prevention (CDC). Vital Signs: Overdoses of Prescription Opioid Pain Relievers --- United States, 1999--2008. Published November 4, 2011. Accessed May 27, 2021. <https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6043a4.htm>
6. Rudd RA, Paulozzi LJ, Bauer MJ, Burleson RW, Carlson RE, Dao D. Increases in Heroin Overdose Deaths — 28 States, 2010 to 2012. Centers for Disease Control and Prevention. Published October 3, 2014. Accessed May 27, 2021. <https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6339a1.htm>
7. Gladden RM. Fentanyl Law Enforcement Submissions and Increases in Synthetic Opioid-Involved Overdose Deaths — 27 States, 2013–2014. *MMWR Morb Mortal Wkly Rep.* 2016;65. doi:10.15585/mmwr.mm6533a2
8. O'Donnell JK. Trends in Deaths Involving Heroin and Synthetic Opioids Excluding Methadone, and Law Enforcement Drug Product Reports, by Census Region — United States, 2006–2015. *MMWR Morb Mortal Wkly Rep.* 2017;66. doi:10.15585/mmwr.mm6634a2
9. Gladden RM, O'Donnell J, Mattson CL, Seth P. Changes in Opioid-Involved Overdose Deaths by Opioid Type and Presence of Benzodiazepines, Cocaine, and Methamphetamine - 25 States, July–December 2017 to January–June 2018. *MMWR Morb Mortal Wkly Rep.* 2019;68(34):737–744. doi:10.15585/mmwr.mm6834a2
10. Centers for Disease Control and Prevention. Coronavirus Disease 2019. Centers for Disease Control and Prevention. Published December 21, 2020. Accessed June 17, 2021. <https://www.cdc.gov/media/releases/2020/p1218-overdose-deaths-covid-19.html>
11. Centers for Disease Control and Prevention (CDC). Drug Overdose Deaths. Published March 25, 2021. Accessed June 17, 2021. <https://www.cdc.gov/drugoverdose/data/statedeaths.html>
12. Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. *Mol Psychiatry.* 2021;26(1):30–39. doi:10.1038/s41380-020-00880-7
13. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med.* 2020;382(8):727–733. doi:10.1056/NEJMoa2001017
14. Czeisler MÉ. Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic — United States, June 24–30, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69. doi:10.15585/mmwr.mm6932a1
15. Substance Abuse and Mental Health Services Administration. Results from the 2019 National Survey on Drug Use and Health: Graphics from the Key Findings Report. Published online 2019. <https://www.samhsa.gov/data/sites/default/files/reports/rpt29393/2019NSDUHFFRBriefSlides082120.pdf>
16. American Society of Addiction Medicine. The Support for Patients and Communities Act (H.R. 6). Accessed June 3, 2021. [https://www.asam.org/advocacy/the-support-for-patients-and-communities-act-\(h.r.-6\)](https://www.asam.org/advocacy/the-support-for-patients-and-communities-act-(h.r.-6))
17. Mattson CL. Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths — United States, 2013–2019. *MMWR Morb Mortal Wkly Rep.* 2021;70. doi:10.15585/mmwr.mm7006a4
18. Centers for Disease Control and Prevention. Increase in Fatal Drug Overdoses Across the United States Driven by Synthetic Opioids Before and During the COVID-19 Pandemic. Published December 17, 2020. Accessed August 12, 2021. <https://emergency.cdc.gov/han/2020/han00438.asp>
19. Baumgartner JC, Radley DC. The Drug Overdose Toll in 2020 and Near-Term Actions for Addressing It. doi:10.26099/gb4y-r129
20. Baumgartner JC, Radley DC. The Spike in Drug Overdose Deaths During the COVID-19 Pandemic and Policy Options to Move Forward. doi:10.26099/gyf5-3z49

21. Abuse NI on D. Part 1: The Connection Between Substance Use Disorders and Mental Illness. National Institute on Drug Abuse. Published --. Accessed May 27, 2021. <https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders/part-1-connection-between-substance-use-disorders-mental-illness>
22. Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry*. 2006;67(2):247-257. doi:10.4088/jcp.v67n0211
23. Torrens M, Gilchrist G, Domingo-Salvany A, psyCoBarcelona Group. Psychiatric comorbidity in illicit drug users: substance-induced versus independent disorders. *Drug Alcohol Depend*. 2011;113(2-3):147-156. doi:10.1016/j.drugalcdep.2010.07.013
24. Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. *Arch Gen Psychiatry*. 2007;64(5):566-576. doi:10.1001/archpsyc.64.5.566
25. Pettinati HM, O'Brien CP, Dundon WD. Current status of co-occurring mood and substance use disorders: a new therapeutic target. *Am J Psychiatry*. 2013;170(1):23-30. doi:10.1176/appi.ajp.2012.12010112
26. Hartz SM, Pato CN, Medeiros H, et al. Comorbidity of severe psychotic disorders with measures of substance use. *JAMA Psychiatry*. 2014;71(3):248-254. doi:10.1001/jamapsychiatry.2013.3726
27. Flórez-Salamanca L, Secades-Villa R, Budney AJ, García-Rodríguez O, Wang S, Blanco C. Probability and predictors of cannabis use disorders relapse: Results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). *Drug Alcohol Depend*. 2013;132(0):127-133. doi:10.1016/j.drugalcdep.2013.01.013
28. Pennay A, Cameron J, Reichert T, et al. A systematic review of interventions for co-occurring substance use disorder and borderline personality disorder. *J Subst Abuse Treat*. 2011;41(4):363-373. doi:10.1016/j.jsat.2011.05.004
29. De Alwis D, Lynskey MT, Reiersen AM, Agrawal A. Attention-Deficit/Hyperactivity Disorder subtypes and substance use and use disorders in NESARC. *Addict Behav*. 2014;39(8):1278-1285. doi:10.1016/j.addbeh.2014.04.003
30. Harstad E, Levy S, COMMITTEE ON SUBSTANCE ABUSE. Attention-Deficit/Hyperactivity Disorder and Substance Abuse. *PEDIATRICS*. 2014;134(1):e293-e301. doi:10.1542/peds.2014-0992
31. Magidson JF, Liu SM, Lejuez CW, Blanco C. Comparison of the Course of Substance Use Disorders among Individuals With and Without Generalized Anxiety Disorder in a Nationally Representative Sample. *J Psychiatr Res*. 2012;46(5):659-666. doi:10.1016/j.jpsychires.2012.02.011
32. Brady KT, Haynes LF, Hartwell KJ, Killeen TK. Substance use disorders and anxiety: a treatment challenge for social workers. *Soc Work Public Health*. 2013;28(3-4):407-423. doi:10.1080/19371918.2013.774675
33. Wolitzky-Taylor K, Operskalski JT, Ries R, Craske MG, Roy-Byrne P. Understanding and treating comorbid anxiety disorders in substance users: review and future directions. *J Addict Med*. 2011;5(4):233-247. doi:10.1097/ADM.0b013e31823276d7
34. National Institute on Drug Abuse. Part 1: The Connection Between Substance Use Disorders and Mental Illness. National Institute on Drug Abuse. Published April 2020. Accessed May 27, 2021. <https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders/part-1-connection-between-substance-use-disorders-mental-illness>
35. National Institute of Mental Illness. Mental Illness. Accessed August 18, 2021. <https://www.nimh.nih.gov/health/statistics/mental-illness>
36. Katz C, El-Gabalawy R, Keyes KM, Martins SS, Sareen J. Risk factors for incident nonmedical prescription opioid use and abuse and dependence: results from a longitudinal nationally representative sample. *Drug Alcohol Depend*. 2013;132(1-2):107-113. doi:10.1016/j.drugalcdep.2013.01.010
37. Goldner EM, Lusted A, Roerecke M, Rehm J, Fischer B. Prevalence of Axis-I psychiatric (with focus on depression and anxiety) disorder and symptomatology among non-medical prescription opioid users in substance use treatment: systematic review and meta-analyses. *Addict Behav*. 2014;39(3):520-531. doi:10.1016/j.addbeh.2013.11.022
38. Benson K. Integrated Mental Health and Substance Use Disorder Treatment | HealthCity. HealthCity. Published June 29, 2020. Accessed May 27, 2021. <https://www.bmc.org/healthcity/population-health/above-integrated-mental-health-and-opioid-use-disorder-treatment>
39. Webster LR. Risk Factors for Opioid-Use Disorder and Overdose : Anesthesia & Analgesia. Accessed May 27, 2021. https://journals.lww.com/anesthesia-analgesia/Fulltext/2017/11000/Risk_Factors_for_Opioid_Use_Disorder_and_Overdose.41.aspx
40. Akbik H, Butler SF, Budman SH, Fernandez K, Katz NP, Jamison RN. Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP). *J Pain Symptom Manage*. 2006;32(3):287-293. doi:10.1016/j.jpainsymman.2006.03.010

41. Webster LR, Cochella S, Dasgupta N, et al. An analysis of the root causes for opioid-related overdose deaths in the United States. *Pain Med*. 2011;12 Suppl 2:S26-35. doi:10.1111/j.1526-4637.2011.01134.x
42. Porucznik CA, Johnson EM, Sauer B, Crook J, Rolfs RT. Studying adverse events related to prescription opioids: the Utah experience. *Pain Med*. 2011;12 Suppl 2:S16-25. doi:10.1111/j.1526-4637.2011.01133.x
43. Substance Abuse and Mental Health Services Administration. Opioid Overdose Prevention Toolkit. Accessed May 27, 2021. <https://store.samhsa.gov/product/Opioid-Overdose-Prevention-Toolkit/SMA18-4742>
44. Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisl KM, Marshall S. Cohort Study of the Impact of High-Dose Opioid Analgesics on Overdose Mortality. *Pain Med*. 2016;17(1):85-98. doi:10.1111/pme.12907
45. Zedler BK, Saunders WB, Joyce AR, Vick CC, Murrelle EL. Validation of a Screening Risk Index for Serious Prescription Opioid-Induced Respiratory Depression or Overdose in a US Commercial Health Plan Claims Database. *Pain Med*. 2018;19(1):68-78. doi:10.1093/pm/pnx009
46. Binswanger IA, Stern MF, Deyo RA, et al. Release from Prison — A High Risk of Death for Former Inmates. *New England Journal of Medicine*. 2007;356(2):157-165. doi:10.1056/NEJMs064115
47. National Institute on Drug. Part 2: Co-occurring Substance Use Disorder and Physical Comorbidities. National Institute on Drug Abuse. Published --. Accessed August 25, 2021. <https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders/part-2-co-occurring-substance-use-disorder-physical-comorbidities>
48. Walker ER, Druss BG. A Public Health Perspective on Mental and Medical Comorbidity. *JAMA*. 2016;316(10):1104-1105. doi:10.1001/jama.2016.10486
49. Stenager E, Christiansen E, Handberg G, Jensen B. Suicide attempts in chronic pain patients. A register-based study. *Scand J Pain*. 2014;5(1):4-7. doi:10.1016/j.sjpain.2013.09.001
50. Hassett AL, Aquino JK, Ilgen MA. The risk of suicide mortality in chronic pain patients. *Curr Pain Headache Rep*. 2014;18(8):436. doi:10.1007/s11916-014-0436-1
51. Cheattle MD, Wasser T, Foster C, Olugbodi A, Bryan J. Prevalence of suicidal ideation in patients with chronic non-cancer pain referred to a behaviorally based pain program. *Pain Physician*. 2014;17(3):E359-367.
52. Painter JM, Malte CA, Rubinsky AD, et al. High inpatient utilization among Veterans Health Administration patients with substance-use disorders and co-occurring mental health conditions. *Am J Drug Alcohol Abuse*. 2018;44(3):386-394. doi:10.1080/00952990.2017.1381701
53. Blanco C, Ali MM, Beswick A, et al. The American Opioid Epidemic in Special Populations: Five Examples. *NAM Perspectives*. Published online October 26, 2020. doi:10.31478/202010b
54. Mental Health Disparities: Diverse Populations. Accessed May 27, 2021. <https://www.psychiatry.org/psychiatrists/cultural-competency/education/mental-health-facts>
55. American Psychiatric Association. What Is Addiction? Published December 2020. Accessed May 27, 2021. <https://www.psychiatry.org/patients-families/addiction/what-is-addiction>
56. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorder, Fifth Edition*.; 2013. Accessed June 17, 2021. <https://doi.org/10.1176/appi.books.9780890425596>
57. Hser YI, Mooney LJ, Saxon AJ, et al. High Mortality among Patients with Opioid Use Disorder in a Large Healthcare System. *J Addict Med*. 2017;11(4):315-319. doi:10.1097/ADM.0000000000000312
58. Hser YI, Evans E, Grella C, Ling W, Anglin D. Long-term course of opioid addiction. *Harv Rev Psychiatry*. 2015;23(2):76-89. doi:10.1097/HRP.0000000000000052
59. Ann Priester M, Browne T, Iachini A, Clone S, DeHart D, Seay KD. Treatment Access Barriers and Disparities Among Individuals with Co-occurring Mental Health and Substance Use Disorders: An Integrative Literature Review. *J Subst Abuse Treat*. 2016;61:47-59. doi:10.1016/j.jsat.2015.09.006
60. Thom B, Mark SG, David MM. The Rapidly Changing Composition of the Global Street Drug Supply and Its Effects on High-Risk Groups for COVID-19. *Current Psychopharmacology*. 2021;10(2):152-168.
61. Woolard R, Baird J, Mello MJ, et al. Injuries, negative consequences, and risk behaviors among both injured and uninjured emergency department patients who report using alcohol and marijuana. *J Emerg Trauma Shock*. 2009;2(1):23-28. doi:10.4103/0974-2700.44679
62. Vitale S, van de Mheen D. Illicit drug use and injuries: A review of emergency room studies. *Drug Alcohol Depend*. 2006;82(1):1-9. doi:10.1016/j.drugalcdep.2005.08.017
63. Chou SP, Chun S, Smith S, Ruan J, Li TK, Grant BF. Episodic heavy drinking, problem drinking and injuries - results of the WHO/NIAAA collaborative emergency room study in South Korea. *Alcohol*. 2012;46(5):407-413. doi:10.1016/j.alcohol.2012.03.002
64. Cherpitel CJ. Alcohol and injuries: a review of international emergency room studies since 1995. *Drug Alcohol Rev*. 2007;26(2):201-214. doi:10.1080/09595230601146686

65. Dahlhamer J. Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults — United States, 2016. *MMWR Morb Mortal Wkly Rep*. 2018;67. doi:10.15585/mmwr.mm6736a2
66. Lauer EA, Henly M, Brucker DL. Prescription opioid behaviors among adults with and without disabilities – United States, 2015–2016. *Disability and Health Journal*. 2019;12(3):519–522. doi:10.1016/j.dhjo.2018.12.001
67. Volkow ND, McLellan AT. Opioid Abuse in Chronic Pain — Misconceptions and Mitigation Strategies. *New England Journal of Medicine*. 2016;374(13):1253–1263. doi:10.1056/NEJMr1507771
68. Hong YR, Xie Z, Yadav S, Tanner R, Striley C, Marlow NM. Opioid Use Behaviors Among People With Disability in the United States: An Analysis of the National Survey on Drug Use and Health. *Journal of Addiction Medicine*. Published online 9900. https://journals.lww.com/journaladdictionmedicine/Fulltext/9900/Opioid_Use_Behaviors_Among_People_With_Disability.26.aspx
69. Substance Abuse and Mental Health Services Administration. Mental and Substance Use Disorder Treatment for People with Physical and Cognitive Disabilities. Accessed August 16, 2022. https://store.samhsa.gov/sites/default/files/d7/priv/pep19-02-00-002_508_022620.pdf
70. Ledingham E, Adams RS, Heaphy D, Duarte A, Reif S. Perspectives of adults with disabilities and opioid misuse: Qualitative findings illuminating experiences with stigma and substance use treatment. *Disability and Health Journal*. 2022;15(2, Supplement):101292. doi:10.1016/j.dhjo.2022.101292
71. Ghertner R, Groves L. THE OPIOID CRISIS AND ECONOMIC OPPORTUNITY: GEOGRAPHIC AND ECONOMIC TRENDS. :22.
72. Dasgupta N, Beletsky L, Ciccarone D. Opioid Crisis: No Easy Fix to Its Social and Economic Determinants. *Am J Public Health*. 2018;108(2):182–186. doi:10.2105/AJPH.2017.304187
73. National Health Care for the Homeless Council. Addressing the Opioid Epidemic How the Opioid Crisis Affects Homeless Populations. Published online August 2017. <https://nhchc.org/wp-content/uploads/2019/08/nhchc-opioid-fact-sheet-august-2017.pdf>
74. Health Care for the Homeless Clinicians' Network. ADAPTING YOUR PRACTICE Recommendations for the Care of Homeless Adults with Chronic Non-Malignant Pain. Published online 2011.
75. Hansen L, Penko J, Guzman D, Bangsberg DR, Miaskowski C, Kushel MB. Aberrant behaviors with prescription opioids and problem drug use history in a community-based cohort of HIV-infected individuals. *J Pain Symptom Manage*. 2011;42(6):893–902. doi:10.1016/j.jpainsymman.2011.02.026
76. Vijayaraghavan M, Penko J, Guzman D, Miaskowski C, Kushel MB. Primary care providers' judgments of opioid analgesic misuse in a community-based cohort of HIV-infected indigent adults. *J Gen Intern Med*. 2011;26(4):412–418. doi:10.1007/s11606-010-1555-y
77. National Institute on Drug Abuse. Drug Facts. Published online June 2020. <https://www.drugabuse.gov/sites/default/files/drugfacts-criminal-justice.pdf>
78. Use of Medication-Assisted Treatment for Opioid Use Disorder in Criminal Justice Settings | SAMHSA Publications and Digital Products. Accessed May 27, 2021. <https://store.samhsa.gov/product/Use-of-Medication-Assisted-Treatment-for-Opioid-Use-Disorder-in-Criminal-Justice-Settings/PEP19-MATUSECJS>
79. Harvard Medical school, Blavatnik Insititute for Health Care Policy. Evidence Based Strategies for Abatement of.... Published October 2020. Accessed June 21, 2021. <https://www.lac.org/resource/evidence-based-strategies-for-abatement-of-harms-from-the-o>
80. Grella CE, Ostle E, Scott CK, Dennis M, Carnavale J. A Scoping Review of Barriers and Facilitators to Implementation of Medications for Treatment of Opioid Use Disorder within the Criminal Justice System. *Int J Drug Policy*. 2020;81:102768. doi:10.1016/j.drugpo.2020.102768
81. Screening and Assessment of Co-Occurring Disorders in the Justice System | SAMHSA Publications and Digital Products. Accessed May 27, 2021. <https://store.samhsa.gov/product/Screening-and-Assessment-of-Co-Occurring-Disorders-in-the-Justice-System/PEP19-SCREEN-CODJS>
82. Association of Maternal & Child Health Programs. Opioids, Domestic Violence, and Mental Health. Published June 2017. Accessed May 27, 2021. <http://www.amchp.org/AboutAMCHP/Newsletters/Pulse/MayJune2017/Pages/Opioids,-Domestic-Violence-and-Mental-Health.aspx>
83. Stone R, Campbell JK, Kinney D, Rothman EF. “He Would Take My Shoes and All the Baby’s Warm Winter Gear so We Couldn’t Leave”: Barriers to Safety and Recovery Experienced by a Sample of Vermont Women With Partner Violence and Opioid Use Disorder Experiences. *J Rural Health*. 2021;37(1):35–44. doi:10.1111/jrh.12518
84. Hui K. Dual Services Needed for Domestic Violence and Opioid Use, Researchers Say. Verywell Health. Accessed May 27, 2021. <https://www.verywellhealth.com/domestic-violence-opioid-rural-women-5082266>
85. Leslie DL, Ba DM, Agbese E, Xing X, Liu G. The economic burden of the opioid epidemic on states: the case of Medicaid. *Am J Manag Care*. 2019;25(13 Suppl):S243–S249.

86. McAdam-Marx C, Roland CL, Cleveland J, Oderda GM. Costs of opioid abuse and misuse determined from a Medicaid database. *J Pain Palliat Care Pharmacother*. 2010;24(1):5-18. doi:10.3109/15360280903544877
87. Adelman PK. Mental and substance use disorders among Medicaid recipients: prevalence estimates from two national surveys. *Adm Policy Ment Health*. 2003;31(2):111-129. doi:10.1023/b:apih.0000003017.78877.56
88. Mark TL, Lubran R, McCance-Katz EF, Chalk M, Richardson J. Medicaid coverage of medications to treat alcohol and opioid dependence. *J Subst Abuse Treat*. 2015;55:1-5. doi:10.1016/j.jsat.2015.04.009
89. Burns ME, Cook ST, Brown L, Tyska S, Westergaard RP. Increasing Medicaid enrollment among formerly incarcerated adults. *Health Services Research*. n/a(n/a). doi:<https://doi.org/10.1111/1475-6773.13634>
90. National Quality Forum (NQF). *Analysis of Measurement Gap Areas and Measure Alignment*. National Quality Forum; 2022. <https://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=94324>
91. Human Services Research Institute. Person-Centered Thinking, Planning, and Practice: A National Environmental Scan of Indicators. Published online December 2019:33.
92. Centers for Disease Control and Prevention (CDC). About Social Determinants of Health (SDOH). Published March 10, 2021. Accessed June 17, 2021. <https://www.cdc.gov/socialdeterminants/about.html>
93. Frohlich KL, Potvin L. Transcending the Known in Public Health Practice. *Am J Public Health*. 2008;98(2):216-221. doi:10.2105/AJPH.2007.114777
94. Fenton JJ, Agnoli AL, Xing G, et al. Trends and Rapidity of Dose Tapering Among Patients Prescribed Long-term Opioid Therapy, 2008-2017. *JAMA Netw Open*. 2019;2(11):e1916271. doi:10.1001/jamanetworkopen.2019.16271
95. Ciccarone D. The rise of illicit fentanyl, stimulants and the fourth wave of the opioid overdose crisis. *Current Opinion in Psychiatry*. 2021;34(4):344-350. doi:10.1097/YCO.0000000000000717
96. CDC. Paving the Road to Health Equity. Published November 30, 2020. Accessed May 25, 2022. https://www.cdc.gov/minorityhealth/publications/health_equity/index.html
97. Centers for Medicare & Medicaid Services. CMS Strategic Plan Pillar: Health Equity. Published online 2022. Accessed August 16, 2022. <https://www.cms.gov/files/document/health-equity-fact-sheet.pdf>
98. NQF. *National Quality Partners Playbook™: Shared Decision Making in Healthcare*. NQF; 2018. Accessed May 25, 2022. <https://store.qualityforum.org/products/national-quality-partners-playbook%e2%84%a2-shared-decision-making>
99. Kuipers SJ, Cramm JM, Nieboer AP. The importance of patient-centered care and co-creation of care for satisfaction with care and physical and social well-being of patients with multi-morbidity in the primary care setting. *BMC Health Services Research*. 2019;19(1):13. doi:10.1186/s12913-018-3818-y
100. National Quality Forum. Addressing Opioid-Related Outcomes Among Individuals With Co-Occurring Behavioral Health Conditions - An Environmental Scan of Quality Measures. Published online April 2021.
101. Compton MT, Shim RS. The Social Determinants of Mental Health. *FOC*. 2015;13(4):419-425. doi:10.1176/appi.focus.20150017
102. NQF. *A Roadmap for Promoting Health Equity and Eliminating Disparities: The Four I's for Health Equity*. National Quality Forum; 2017. Accessed June 17, 2021. https://www.qualityforum.org/Publications/2017/09/A_Roadmap_for_Promoting_Health_Equity_and_Eliminating_Disparities_The_Four_I_s_for_Health_Equity.aspx
103. Kulesza M, Larimer ME, Rao D. Substance Use Related Stigma: What we Know and the Way Forward. *J Addict Behav Ther Rehabil*. 2013;2(2):782. doi:10.4172/2324-9005.1000106
104. Smith LR, Earnshaw VA, Copenhaver MM, Cunningham CO. Substance Use Stigma: Reliability and validity of a theory-based scale for substance-using populations. *Drug Alcohol Depend*. 2016;162:34-43. doi:10.1016/j.drugalcdep.2016.02.019
105. Hansen H, Roberts SK. Two tiers of biomedicalization: METHADONE buprenorphine and the racial politics of addiction treatment. *Critical Perspectives on Addiction*. Published online 2012:79-102. doi:10.1108/S1057-6290(2012)0000014008
106. Hansen HB, Siegel CE, Case BG, Bertollo DN, DiRocco D, Galanter M. Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City. *J Behav Health Serv Res*. 2013;40(3):367-377. doi:10.1007/s11414-013-9341-3
107. Jones CM, McCance-Katz EF. Co-occurring substance use and mental disorders among adults with opioid use disorder. *Drug Alcohol Depend*. 2019;197:78-82. doi:10.1016/j.drugalcdep.2018.12.030
108. Bailey A, Hayes K, Katch H, Solomon J. Medicaid Is Key to Building a System of Comprehensive Substance Use Care for Low-Income People. Centers on Budget and Policy Priorities. Published March 18, 2021. Accessed June 17, 2021. <https://www.cbpp.org/research/health/medicaid-is-key-to-building-a-system-of-comprehensive-substance-use-care-for-low>

109. Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment. *Am J Public Health*. 2015;105(8):e55-e63. doi:10.2105/AJPH.2015.302664
110. Haffajee RL, Lin LA, Bohnert ASB, Goldstick JE. Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder. *JAMA Netw Open*. 2019;2(6). doi:10.1001/jamanetworkopen.2019.6373
111. Nguemeni Tiako MJ. Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19. *J Subst Abuse Treat*. 2021;122:108214. doi:10.1016/j.jsat.2020.108214
112. Opioid Response Network. The Opioid Epidemic and COVID-19: How Social Determinants of Health Create Differential Impacts.
113. Scott K, Lewis CC. Using Measurement-Based Care to Enhance Any Treatment. *Cogn Behav Pract*. 2015;22(1):49-59. doi:10.1016/j.cbpra.2014.01.010
114. The Joint Commission. Outcome Measures Standard. Accessed May 27, 2021. <https://www.jointcommission.org/accreditation-and-certification/health-care-settings/behavioral-health-care/outcome-measures-standard>
115. Vilsaint CL, Kelly JF, Bergman BG, Groshkova T, Best D, White W. Development and validation of a Brief Assessment of Recovery Capital (BARC-10) for alcohol and drug use disorder. *Drug Alcohol Depend*. 2017;177:71-76. doi:10.1016/j.drugalcdep.2017.03.022
116. Cacciola JS, Alterman AI, DePhillippis D, et al. Development and initial evaluation of the Brief Addiction Monitor (BAM). *J Subst Abuse Treat*. 2013;44(3):256-263. doi:10.1016/j.jsat.2012.07.013
117. Williams AR, Nunes EV, Olfson M. To Battle The Opioid Overdose Epidemic, Deploy The 'Cascade of Care' Model | Health Affairs. Health Affairs. Published March 13, 2017. Accessed June 3, 2021. <https://www.healthaffairs.org/doi/10.1377/hblog20170313.059163/full/>
118. Williams AR, Nunes EV, Bisaga A, Levin FR, Olfson M. Development of a Cascade of Care for responding to the opioid epidemic. *Am J Drug Alcohol Abuse*. 2019;45(1):1-10. doi:10.1080/00952990.2018.1546862
119. Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. *Lancet*. 2019;393(10182):1760-1772. doi:10.1016/S0140-6736(18)33078-2
120. Atkins J, Dopp AL, Temaner and EB. Combatting the Stigma of Addiction— The Need for a Comprehensive Health System Approach. *NAM Perspectives*. Published online November 9, 2020. doi:10.31478/202011d
121. Nguemeni Tiako MJ. Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19. *J Subst Abuse Treat*. 2021;122:108214. doi:10.1016/j.jsat.2020.108214
122. National Quality Forum. Priority Setting for Healthcare Performance Measurement: Addressing Performance Measure Gaps in Care Coordination. Aug 2014.
123. National Quality Forum. Care Coordination Measures Technical Report. Published online August 2017. https://www.qualityforum.org/Publications/2017/08/Care_Coordination_Measures_Technical_Report.aspx
124. Office of the Commissioner. FDA In Brief: FDA requires new warnings for gabapentinoids about risk of respiratory depression. FDA. Published December 20, 2019. Accessed May 27, 2021. <https://www.fda.gov/news-events/fda-brief/fda-brief-fda-requires-new-warnings-gabapentinoids-about-risk-respiratory-depression>
125. Harm Reduction Principles. National Harm Reduction Coalition. Accessed May 27, 2021. <https://harmreduction.org/about-us/principles-of-harm-reduction/>
126. National Quality Forum. NQF: Person Centered Planning and Practice Final Report. Published July 31, 2020. Accessed August 12, 2021. https://www.qualityforum.org/Publications/2020/07/Person_Centered_Planning_and_Practice_Final_Report.aspx
127. National Quality Forum. Enhancing Access to Medication Assisted Treatment. Published online 2019.
128. Madras BK, Ahmad NJ, Wen J, et al. Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers Within the Treatment System. *NAM Perspectives*. Published online April 27, 2020. doi:10.31478/202004b
129. Albertson EM, Scannell C, Ashtari N, Barnert E. Eliminating Gaps in Medicaid Coverage During Reentry After Incarceration. *Am J Public Health*. 2020;110(3):317-321. doi:10.2105/AJPH.2019.305400
130. NQF. *Risk Adjustment for Socioeconomic Status or Other Sociodemographic Factors*. National Quality Forum; 2014. Accessed June 4, 2021. https://www.qualityforum.org/Publications/2014/08/Risk_Adjustment_for_Socioeconomic_Status_or_Other_Sociodemographic_Factors.aspx
131. Economic Insecurity and Deaths of Despair in US Counties | American Journal of Epidemiology | Oxford Academic. Accessed June 17, 2021. <https://academic.oup.com/aje/article/188/12/2131/5479232?login=true>

132. Medicaid. Section 1115 Demonstrations: Substance Use Disorders, Serious Mental Illness, and Serious Emotional Disturbance. Accessed May 27, 2021. <https://www.medicaid.gov/medicaid/section-1115-demonstrations/1115-substance-use-disorder-demonstrations/section-1115-demonstrations-substance-use-disorders-serious-mental-illness-and-serious-emotional-disturbance/index.html>
133. New Hampshire Department of Health and Human Services. Substance Use Disorder Treatment and Recovery Access Section 1115(a). Published online August 21, 2020.
134. SAMHSA. SAMHSA Awards Vibrant Emotional Health the Grant to Administer 988 Dialing Code for the National Suicide Prevention Lifeline. Published June 16, 2021. Accessed September 8, 2021. <https://www.samhsa.gov/newsroom/press-announcements/202106161430>
135. Khatri UG, Howell BA, Winkelman TNA. Medicaid Expansion Increased Medications For Opioid Use Disorder Among Adults Referred By Criminal Justice Agencies. *Health Affairs*. 2021;40(4):562-570. doi:10.1377/hlthaff.2020.01251
136. Frank HE, Grumbach NM, Conrad SM, Wheeler J, Wolff J. Mental health services in primary care: Evidence for the feasibility of telehealth during the COVID-19 pandemic. *Journal of Affective Disorders Reports*. 2021;5:100146. doi:10.1016/j.jadr.2021.100146
137. Stein BD, Saloner B, Schuler MS, Gurvey J, Sorbero M, Gordon AJ. Concentration of Patient Care Among Buprenorphine-Prescribing Clinicians in the US. *JAMA*. 2021;325(21):2206-2208. doi:10.1001/jama.2021.4469
138. Integrated Mental Health and Substance Use Disorder Treatment | HealthCity. Boston Medical Center. Published June 29, 2020. Accessed May 27, 2021. <https://www.bmc.org/healthcity/population-health/above-integrated-mental-health-and-opioid-use-disorder-treatment>